GlassScriptPhysician profile
Salman Ahmad
NPI 1043281025
$8,092.82
in general payments reported to CMS, 2019-2025
53 companies · $760 in 2025
The $760 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $1,033 · 2021: $1,476 · 2022: $1,060 · 2023: $1,287 · 2024: $1,063 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,489 · Travel and Lodging: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,488.74 |
| Travel and Lodging | $620.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,078.30 | 2019-2025 | Rinvoq, Skyrizi, Qulipta |
| Pfizer INC. | $967.30 | 2019-2024 | |
| Amgen INC. | $692.44 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbott Laboratories | $653.51 | 2021-2023 | Ensite Precision |
| Lilly USA, LLC | $498.16 | 2020-2023 | Mounjaro, Jardiance, Emgality |
| Horizon Therapeutics Plc | $261.09 | 2019-2022 | |
| Radius Health, INC. | $220.63 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $191.96 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $187.67 | 2024-2025 | Rexulti, Nuedexta |
| Mannkind Corporation | $160.48 | 2019-2023 | Afrezza |
| Scilex Pharmaceuticals INC. | $125.66 | 2022-2023 | Ztlido |
| Glaxosmithkline, LLC. | $118.79 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Biogen, INC. | $114.49 | 2020-2021 | |
| Novo Nordisk INC | $104.33 | 2019 | |
| Sunovion Pharmaceuticals INC. | $99.92 | 2019-2020 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.